Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2024, and provided ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

Trump’s tariffs put copper market in the hot seat; Iron ore still a defensive play, but risks loom; How all this could impact ...

Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...

T-DM1 was tolerable in HER2-positive biliary tract adenocarcinoma but did not significantly improve progression-free survival ...

But that’s what 25-year-old Janice Hernandez is facing, according to a recent TikTok video with 3.6 million views. The bill ...

Failed to fetch dynamically imported module: https://au.finance.yahoo.com/assets/_app/immutable/nodes/103.Dy1Aqtl6.js ...

Reddit user's husband says ‘life is too short’ to save — now she’s protecting her inheritance. Is she right? In marriage, the idea of sharing everything — what’s mine is yours — feels like a given.

Essentially, if Indonesia doesn’t shift the bar, they will not have enough nickel to meet domestic demand – and that will ...

T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer.

The latest data from the Federal Reserve indicates that households of Americans aged 55 to 64 have a median of $185,000 in ...

throw=DM1_streamline_managing-money ... my lack of detail,” he said. “You can't.” Bill’s situation illustrates why boosted earnings is only part of the battle. He told Ramsey the family spends $12,000 ...